Cartilage matrix metabolism pathway

The "cartilage matrix metabolism pathway" refers not to a single molecule or receptor but rather to the complex network of cellular processes that regulate the synthesis and degradation of extracellular matrix components in articular cartilage. This includes anabolic activities—such as production of type II collagen and aggrecan by chondrocytes—and catabolic activities mediated by enzymes like MMPs that degrade these structural proteins. The balance between these processes maintains cartilage integrity; disruption leads to diseases such as osteoarthritis. Key regulators include signaling pathways like Wnt/β-catenin—which promotes catabolism when overactivated—as well as noncoding RNAs such as lncRNAs and miR‑148a that fine-tune gene expression related to ECM turnover. While individual molecules within this network can be therapeutic targets or biomarkers for disease progression/intervention efficacy, the overall "cartilage matrix metabolism pathway" is best understood as a functional concept describing tissue homeostasis rather than a discrete druggable target.[1][2][3][5] The term “cartilage matrix metabolism pathway” does not refer to an individual molecular target but encompasses multiple interacting proteins, genes, RNAs, enzymes (like MMPs), structural proteins (collagen II/aggrecan), cell types (chondrocytes), and regulatory signals.[4] Therefore it should not be considered a canonical therapeutic target on its own. There is something incorrect about using “Cartilage matrix metabolism pathway” as a drug target name—it describes an entire biological process/pathway involving many targets rather than one specific molecule/receptor/enzyme suitable for structured pharmacological targeting.[5]

Other names

Cartilage extracellular matrix metabolismECM metabolism in cartilageCartilage ECM turnoverArticular cartilage matrix regulation